Cost implications of alternative treatments for AIDS patients with cryptococcal meningitis. Comparison of fluconazole and amphotericin B-based therapies.
The extra demands placed upon health care resources by management of AIDS patients have increased the focus on cost implications of therapeutic alternatives. Cryptococcal meningitis is a common life-threatening infection in AIDS patients, usually treated with amphotericin B, often in combination with flucytosine. Administered intravenously, this therapy is associated with frequent and often severe side effects. Fluconazole is a new alternative which can be given orally once daily and has fewer such side effects. The purpose of this study was to examine the cost implications of these different therapies for both primary and maintenance treatment of cryptococcal meningitis. Comparison of these two therapies in recent clinical trials has indicated that fluconazole is at least as effective as amphotericin B, and therefore cost-minimisation analysis is an appropriate method to study the economic consequences of the alternative treatments. Patient management and resource-use information for both treatments was obtained using a modified Delphi technique with a panel of European physicians experienced in the treatment of this disease, and three models were developed to reflect the variability of practice evident among the panel members. U.K. health care costs were used to value these resources. The results indicated that, despite the higher cost of the drug itself, the costs associated with fluconazole were likely to be markedly less than those for amphotericin B for primary treatment, and similar or slightly cheaper for maintenance treatment. Over 1 year of treatment, the saving from the use of fluconazole would be in the range of 4000-14,000 pounds.
Buxton
M J
MJ
Health Economics Research Group, Brunel University, Uxbridge, U.K.
Dubois
D J
DJ
Turner
R R
RR
Sculpher
M J
MJ
Robinson
P A
PA
Searcy
C
C
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications* / Q000191:economics; D000284:Administration, Oral; D000666:Amphotericin B / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003365:Costs and Cost Analysis; D003453:Cryptococcosis / Q000188:drug therapy / Q000191:economics*; D003697:Delphi Technique; D004359:Drug Therapy, Combination; D015725:Fluconazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005437:Flucytosine / Q000008:administration & dosage / Q000627:therapeutic use*; D006760:Hospitalization / Q000191:economics; D006801:Humans; D007262:Infusions, Intravenous; D008581:Meningitis / Q000188:drug therapy / Q000191:economics* / Q000382:microbiology; D008962:Models, Theoretical; D011795:Surveys and Questionnaires
D000666:Amphotericin B; D015725:Fluconazole; D005437:Flucytosine